CLOs on the Move

RootPath Genomics

www.rootpath.com

 
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Mirus Bio

Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ESSA Pharma

As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.

Lake Pharma

LakePharma is the leading biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal.

Seisa Medical

Seisa Medical is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.